USPTO serial 78555670
XVIR
Reviewed by CopyMark Law Group
Reg. 3385323Status 710
- Filing date
- Status date
- Registration date
- Feb 19, 2008
- Examiner
- DEFORD, JEFFREY S
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with XVIR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Matthew J. Smith
Brian B. Diekhoff Polsinelli Shughart PC100 South Fourth StreetSuite 1000St. Louis, MO 63102Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical products for research use and for use in the manufacture of pharmaceuticals, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, aptamers consisting essentially of L-nucleotides, short limiting RNA molecules without specific limitation to the number of nucleotides, antisense oligonucleotides, ribozymes, decoy oligonucleotides | SECTION 8 - CANCELLED | — |
| 005 | Chemical products for medical and veterinary clinical use, namely nucleic acids, vectors, plasmids, viruses, peptides and proteins, lipids, lipid coated proteins, lipid coated nucleic acids, lipid coated viruses, lipid coated vectors, lipid coated plasmids, antibodies, anticalines, aptamers, spiegelmers, siRNA molecules, antisense oligonucleotides, ribosomes, decoy oligonucleotides; Pharmaceutical and veterinary preparations, namely slimming agents, appetite suppressants, acidosis therapeutics, analeptics, antihypoximics, analgesics, antirheumatic drugs, antihelmintics, antiallergics, anti-anemia drugs, antiarrhythmics, antibiotics, anti-infective agents, antidementics, nootropics, antidiabetics, antidotes, antiemetics, antivertiginosics, antiepileptics, antihemorrhagics, antifibrinolytics, hemostatics, antihypertonics, antihypoglycemics, antihypotonics, anticoagulants, antimycotics, antiparasitic agents, antiphlogistics, expectorants, agents for use in atherosclerosis, balneotherapeutics and preparations for heat therapy, beta receptor blocking agents, calcium channel blocking agents and inhibitors of the renin-angiotensin-system, broncholytics, antiasthmetics, cholagoguegics and biliary tract therapeutics, cholinergics, corticoids, dermatics, general purpose disinfectants, antiseptics, dietetic foods adapted for medical use, alimentary therapeutics, diagnostic preparations for medical and veterinary use, diuretics, preparations for the stimulation of blood circulation, fibrinolytics, geriatric agents for the treatment of stress and age-related diseases, geriatric nutritional supplements, agents for use in gout, agents for use in flu and in catarrhal fever, gynecological agents, hemorrhoid agents, hepatics, hypnotics, sedatives, cardiac therapeutics, agents for removal of dental stain, agents for reconstitution of gums, materials for dental fillings and for dental sealing purposes, corona agents, laxatives, antilipaemics, local anesthetics, neural therapeutics, gastro-intestinal agents, migraine agents, mineral supplements, mouth and pharyngeal therapeutics, muscle relaxants, narcotics, neuropathical agents and other neurotropic agents, ophthalmic preparations, agents for use in osteoporosis, calcium metabolism modifying agents, agents for use in Parkinson's Disease and other agents against disturbances of the extrapyramidal system, psychotropic agents, rhinologics, sinositic agents, roborants, thyroidal therapeutics, spasmolytics, inhibitors of thrombocyte aggregation, tuberculosis agents, altemants, urologics, venous agents, vitamins, cytostatics and other antineoplastic agents and protectives, homeopathic supplements; and Pharmaceutical and veterinary preparations in the nature of viruses, viruses for oncolysis, viruses for gene therapy, viruses for delivery of pharmaceutically active compounds, viruses for restoration of drug sensitivity, viruses for restoration of apoptosis, and viruses for cancer therapy, all for clinical use | SECTION 8 - CANCELLED | — |
| 009 | Scientific laboratory equipment, namely, photometers, mass spectrometers, ELISA readers, positron emission tomography (PET) scanners, thermocyclers, nuclear magnetic resonance (NMR) spectrometers, fluorescence-activated cell sorters, cell counters, and blotting devices using electric, magnetic, or capillary forces for material transfer | SECTION 8 - CANCELLED | — |
| 042 | Scientific and medical research services in biology, molecular biology, chemistry, biochemistry, genetics, molecular genetics, and pathology; scientific and medical research services for third parties, namely, determination of viral particles, determination and sequencing of viral genome, determination of nuclear YB-1 binding protein, determination of drug resistance in samples, determination of radiation resistance in samples, design of viral vectors, design of plasmid vectors, design of viruses and in particular oncolytic viruses; scientific and medical research services, namely, design and performance of clinical trials | SECTION 8 - CANCELLED | — |
| 044 | Medical services featuring physicians and surgeons; veterinary services; medical services, namely, determination of individual disease risk, determination of individual cancer therapy, identifying patient groups treatable by oncolytic viruses, individual health care and managed health care services | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks owned by XVir Therapeutics GmbH
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named XVIR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 26, 2014 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 22, 2011 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Feb 3, 2010 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Feb 3, 2010 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Feb 19, 2008 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 11, 2008 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Dec 28, 2007 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Dec 28, 2007 | D1BR | TEAS DELETE 1(B) BASIS RECEIVED | — |
| Nov 15, 2007 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 25, 2007 | PAPER RECEIVED | — | |
| Jun 29, 2007 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jun 29, 2007 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Jun 29, 2007 | EXT1 | SOU EXTENSION 1 FILED | — |
| Jun 29, 2007 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jan 2, 2007 | NOAM | NOA MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 12, 2006 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 10, 2006 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 20, 2006 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 18, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 11, 2006 | ALIE | ASSIGNED TO LIE | — |
| Aug 3, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 3, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 3, 2006 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 3, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Aug 3, 2006 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Jul 10, 2006 | PBCR | WITHDRAWN FROM PUB - OG REVIEW QUERY | — |
| Jun 16, 2006 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Jun 2, 2006 | ALIE | ASSIGNED TO LIE | — |
| May 31, 2006 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 31, 2006 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 31, 2006 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 31, 2006 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Dec 7, 2005 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 7, 2005 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 5, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 21, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 21, 2005 | PAPER RECEIVED | — | |
| Oct 14, 2005 | ACEC | AMENDMENT FROM APPLICANT ENTERED | — |
| Oct 4, 2005 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 4, 2005 | PAPER RECEIVED | — | |
| Aug 31, 2005 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 31, 2005 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Aug 26, 2005 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 7, 2005 | NWAP | NEW APPLICATION ENTERED | — |
| Jan 31, 2005 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Jan 31, 2005 | PAPER RECEIVED | — |